<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406132</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK03</org_study_id>
    <nct_id>NCT01406132</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate pharmacokinetics, in particular the routes of&#xD;
      excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled&#xD;
      ASP015K.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be admitted to the clinical research unit and confined for a minimum&#xD;
      of 8 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment through radiographic and high performance liquid chromatography (HPLC) analysis of blood, urine and feces samples</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics of ASP015K</condition>
  <arm_group>
    <arm_group_label>ASP015K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP015K</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a body weight of at least 45 kg and a body mass index (BMI) between 18&#xD;
             and 32 kg/m2, inclusive&#xD;
&#xD;
          -  The subject has been a non-smoker for at least 3 months prior to check-in&#xD;
&#xD;
          -  The subject agrees to sexual abstinence, is surgically sterile (with documentation&#xD;
             provided by a healthcare professional), or is using a medically acceptable method to&#xD;
             prevent pregnancy during the study period&#xD;
&#xD;
          -  The subject's clinical laboratory test results are within normal limits&#xD;
&#xD;
          -  The subject is medically healthy, with no clinically significant medical history or&#xD;
             abnormalities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a history of any clinically significant gastrointestinal, cardiac,&#xD;
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&#xD;
             neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy&#xD;
             excluding non-melanoma skin cancer&#xD;
&#xD;
          -  The subject has a history of malabsorption syndrome or previous gastrointestinal&#xD;
             surgery that could affect drug absorption or metabolism&#xD;
&#xD;
          -  The subject has a recent history of irregular defecation, such as constipation or&#xD;
             diarrhea&#xD;
&#xD;
          -  The subject has a history of drug or alcohol abuse, or a positive urine screen for&#xD;
             alcohol or drugs of abuse/illegal drugs&#xD;
&#xD;
          -  The subject has had treatment with prescription drugs or complementary and alternative&#xD;
             medicines (CAM) within 14 days prior to study drug administration, or over the counter&#xD;
             (OTC) medication within past week&#xD;
&#xD;
          -  The subject has/had a symptomatic, viral, bacterial (including upper respiratory&#xD;
             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in&#xD;
&#xD;
          -  The subject is known positive for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  The subject has a positive test for hepatitis C antibody, or positive test for&#xD;
             hepatitis B antigen (HBsAg)&#xD;
&#xD;
          -  The subject has positive tuberculosis (TB) or Quantiferon Gold test&#xD;
&#xD;
          -  The subject has received an experimental agent within 30 days or five half-lives,&#xD;
             whichever is longer, prior to study drug administration&#xD;
&#xD;
          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or&#xD;
             more, or received a transfusion of any blood or blood products within 60 days or&#xD;
             donated plasma within 7 days prior to clinic admission&#xD;
&#xD;
          -  The subject has had exposure to significant radiation (eg, serial x-ray or computed&#xD;
             tomography scans, barium meal, current employment in a job requiring radiation&#xD;
             exposure monitoring) within 12 months prior to check-in&#xD;
&#xD;
          -  The subject has participated in a radio-labeled-study within the last 6 months,&#xD;
             participated in more than one other radio-labeled study within the past 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CCRU)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

